ArticleHealth science reports2026
Therapeutic Potential of Mesenchymal Stem Cells in Pediatric Kidney Disorders: A Comprehensive Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney diseases in children present significant health challenges, often leading to complications and reduced quality of life. Mesenchymal stem cell (MSC) therapy shows promise for pediatric kidney disorders. This review evaluates current evidence on MSC applications in pediatric nephrology, focusing on mechanisms, delivery methods, and outcomes. Methods: We analyzed preclinical and clinical studies of MSC therapy for pediatric acute kidney injury (AKI), chronic kidney disease (CKD), glomerular disorders, and Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), comparing pediatric and adult applications. Results: MSCs exert therapeutic effects through immunomodulation, tissue regeneration, anti-fibrotic activity, and paracrine mechanisms. Different sources (bone marrow, umbilical cord, adipose) show varying efficacy. Delivery methods significantly impact outcomes: intravenous administration is well-tolerated but limited (2%-5% kidney delivery), while local infusion enhances targeting (10%-20%). Clinical studies show improved renal function: decreased creatinine in AKI, reduced albumin-to-creatinine ratio in CKD, and decreased proteinuria in nephrotic syndrome. Pediatric applications differ from adult ones in disease etiology, physiological considerations, therapeutic goals, and safety requirements. Conclusion: MSC therapy shows promising potential for pediatric kidney disorders, with preliminary evidence supporting safety and efficacy. Challenges remain in optimizing cell sources, standardizing protocols, and establishing long-term safety. Future research should focus on biomarker identification, pediatric-specific models, and protocol standardization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.